关于“金砖+”国家乳腺癌负担的最新见解:利用2019年全球疾病负担研究对新兴经济体主要国家的健康影响
More recent insights into the breast cancer burden across BRICS-Plus: Health consequences in key nations with emerging economies using the global burden of disease study 2019.
作者信息
Mubarik Sumaira, Luo Lisha, Iqbal Mujahid, Bai Jianjun, Yu Chuanhua
机构信息
Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan, China.
Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
出版信息
Front Oncol. 2023 Jan 24;13:1100300. doi: 10.3389/fonc.2023.1100300. eCollection 2023.
BACKGROUND
Brazil, Russia, India, China, South Africa, and 30 other Asian nations make up the BRICS-Plus, a group of developing countries that account for about half of the world's population and contribute significantly to the global illness burden. This study aimed to analyzed the epidemiological burden of female breast cancer (BC) across the BRICS-Plus from 1990 to 2019 and studied the associations with age, period, birth cohort and countries' sociodemographic index (SDI).
METHODS
The BC mortality and incidence estimates came from the 2019 Global Burden of Disease Study. We estimated cohort and period effects in BC outcomes between 1990 and 2019 using age-period-cohort (APC) modeling. The maximum likelihood (ML) of the APC-model Poisson with log (Y) based on the natural-spline function was used to estimate the rate ratio (RR). We used annualized rate of change (AROC) to quantify change over the previous 30 years in BC across BRICS-Plus and compare it to the global.
RESULTS
In 2019, there were about 1.98 million female BC cases (age-standardized rate of 45.86 [95% UI: 41.91, 49.76]) and 0.69 million deaths (age-standardized rate of 15.88 [95% UI: 14.66, 17.07]) around the globe. Among them, 45.4% of incident cases and 51.3% of deaths were attributed to the BRICS-Plus. China (41.1% cases and 26.5% deaths) and India (16.1% cases and 23.1% deaths) had the largest proportion of incident cases and deaths among the BRICS-Plus nations in 2019. Pakistan came in third with 5.6% cases and 8.8% deaths. Over the past three decades, from 1990 to 2019, the BRICS-Plus region's greatest AROC was seen in Lesotho (2.61%; 95%UI: 1.99-2.99). The birth cohort impacts on BC vary significantly among the BRICS-Plus nations. Overall, the risk of case-fatality rate tended to decline in all BRICS-Plus nations, notably in South Asian Association for Regional Cooperation (SAARC) and China-ASEAN Free Trade Area (China-ASEAN FTA) countries, and the drop in risk in the most recent cohort was lowest in China and the Maldives. Additionally, there was a substantial negative link between SDI and case fatality rate (r= -0.91, <0.001; r= -0.89, 0.001) in the BRICS-Plus in both 1990 and 2019, with the Eurasian Economic Union (EEU) nations having the highest case fatality rate.
CONCLUSIONS
The BC burden varies remarkably between different BRICS-Plus regions. Although the BRICS' efforts to regulate BC succeeded, the overall improvements lagged behind those in high-income Asia-Pacific nations. Every BRICS-Plus country should strengthen specific public health approaches and policies directed at different priority groups, according to BRIC-Plus and other high-burden nations.
背景
巴西、俄罗斯、印度、中国、南非以及其他30个亚洲国家组成了金砖国家扩员后的集团(BRICS-Plus),这是一群发展中国家,占世界人口约一半,对全球疾病负担有重大贡献。本研究旨在分析1990年至2019年期间金砖国家扩员后的集团中女性乳腺癌(BC)的流行病学负担,并研究其与年龄、时期、出生队列以及各国社会人口指数(SDI)的关联。
方法
乳腺癌死亡率和发病率估计来自2019年全球疾病负担研究。我们使用年龄-时期-队列(APC)模型估计了1990年至2019年期间乳腺癌结局的队列和时期效应。基于自然样条函数的对数(Y)的APC模型泊松最大似然法(ML)用于估计率比(RR)。我们使用年化变化率(AROC)来量化过去30年金砖国家扩员后的集团中乳腺癌的变化,并将其与全球情况进行比较。
结果
2019年,全球约有198万例女性乳腺癌病例(年龄标准化率为45.86[95%UI:41.91,49.76])和69万例死亡(年龄标准化率为15.88[95%UI:14.66,17.07])。其中,45.4%的新发病例和51.3%的死亡归因于金砖国家扩员后的集团。2019年,中国(41.1%的病例和26.5%的死亡)和印度(16.1%的病例和23.1%的死亡)在金砖国家扩员后的集团国家中所占新发病例和死亡比例最大。巴基斯坦以5.6%的病例和8.8%的死亡位列第三。在过去三十年中,从1990年到2019年,金砖国家扩员后的集团地区年化变化率最高的是莱索托(莱索托(2.61%;95%UI:1.99 - 2.99))。出生队列对乳腺癌的影响在金砖国家扩员后的集团国家中差异显著。总体而言,金砖国家扩员后的集团所有国家的病死率风险都趋于下降,特别是在南亚区域合作联盟(SAARC)和中国-东盟自由贸易区(中国-东盟FTA)国家,而最近队列中风险下降在中国和马尔代夫最低。此外,1990年和2019年金砖国家扩员后的集团中SDI与病死率之间均存在显著负相关(r = -0.91,<0.001;r = -0.89,<0.001),欧亚经济联盟(EEU)国家的病死率最高。
结论
金砖国家扩员后的集团不同地区之间乳腺癌负担差异显著。尽管金砖国家在乳腺癌防控方面的努力取得了成功,但总体改善仍落后于高收入亚太国家。根据金砖国家扩员后的集团和其他高负担国家的情况,每个金砖国家扩员后的集团国家都应加强针对不同优先群体的特定公共卫生方法和政策。